BMO Capital analyst Joanne Wuensch noted that Washington Analysis has released a report on iRhythm, detailing its analysis of expected changes for the reimbursement of iRhythm's Zio patch. While Wuensch said she agrees with Washington Analysis' view that the reimbursement change to a Category I code may not be implemented until 2021/2022, she disagrees with their view that the suggested reimbursement rate may be cut to $106-170 from the current Category III code rate of $310. There is no imminent change in reimbursement and her conversations with management indicate that they believe there is as much chance that the Category I rate increases as it decreases, Wuensch tells investors. She reiterates her Outperform rating and $105 price target on iRhythm shares.